Brickell Biotech: Up on launching late-stage U.S. trial of excess sweat therapy

Fresh Tracks Therapeutics

06/10/2020 16:38

** Drug developer's shares  BBI.O  rise 3.7% to $0.92
    ** Co initiates first U.S. late-stage clinical study
evaluating sofpironium bromide gel as a potential treatment for
primary axillary hyperhidrosis, which is characterized by
excessive sweating in the armpits  urn:newsml:reuters.com:*:nGNX6hZPr9
    ** Shares rose as much as ~5% on Sept. 25 after co's
Japanese development partner, Kaken Pharmaceutical, received
approval to manufacture and market sofpironium bromide gel (5%)
in Japan  urn:newsml:reuters.com:*:nL3N2GM2MK
    ** BBI shares have fallen ~38% YTD 

 (Reporting By Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))